Mediators of Inflammation (Jan 2000)

Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients

  • Sasan Roayaie,
  • Patricia A. Sheiner,
  • Sukru Emre,
  • Steven Guy,
  • Myron E. Schwartz,
  • Peter Boros,
  • Charles M. Miller

DOI
https://doi.org/10.1080/09629350020002877
Journal volume & issue
Vol. 9, no. 3-4
pp. 141 – 146

Abstract

Read online

OKT3, a murine monoclonal antibody specific to the human CD3 complex, induces immunosuppression by depletion of T cells. Administration of OKT3 results in significant release of proinflammatory cytokines, such as TNFα and IL1β. Liver recipients who experience rejection within 3 weeks after transplantation with OKT3 prophylaxis recover their T cells by postoperative day 10 despite complete initial clearance.